As we already know, MJFF et. al. and Georgetown U. are both planning separate controlled clinical trials to determine the potential disease-modifying efficacy of Nilotinib (Tasigna) in PD patients. Today, we just received notice that a small biotech company, Inhibikase Therapeutics, has received FDA approval to begin double-blinded, placebo-controlled trials for Nilotinib and Dasatinib (Sprycel - Bristol-Myers). The trials will try to evaluate the ability of both drugs (vs placebo) to slow or reverse progression in Stage 2 and 3 PD patients. It will be held at one test site over a 6 month period.

The reason Inhibikase is conducting the studies is really more of a proof of concept for two new drugs that they are researching. They are developing two Abelson tyrosine inhibitors that are as much as 60 times more potent than the ones currently on the market (Nilotinib, Dasatinib, Gleevec, etc.).

Inhibikase Therapeutics, Inc. Receives FDA Clearance To Initiate Clinical Trials For Potential